The price of Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares last traded on Wall Street fell -6.92% to $0.72.
KPTI stock price is now -9.02% away from the 50-day moving average and -22.09% away from the 200-day moving average. The market capitalization of the company currently stands at $90.36M.
With the price target of $8, Piper Sandler recently initiated with Overweight rating for Karyopharm Therapeutics Inc (NASDAQ: KPTI). On November 04, 2022, RBC Capital Mkts Upgraded its previous ‘Sector Perform’ rating to ‘Outperform’ on the stock increasing its target price from $7 to quote $10, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, Paulson Richard A., President and CEO sold 4,055 shares of the company’s stock on Jan 06 ’25. The stock was sold for $3,175 at an average price of $0.78. Upon completion of the transaction, the President and CEO now directly owns 1,124,257 shares in the company, valued at $0.81 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 04 ’24, President and CEO Paulson Richard A. sold 3,620 shares of the business’s stock. A total of $2,932 was realized by selling the stock at an average price of $0.81. This leaves the insider owning 1,128,312 shares of the company worth $0.81 million. A total of 8.58% of the company’s stock is owned by insiders.
During the past 12 months, Karyopharm Therapeutics Inc has had a low of $0.58 and a high of $1.95. The fifty day moving average price for KPTI is $0.78924 and a two-hundred day moving average price translates $0.922395 for the stock.
The latest earnings results from Karyopharm Therapeutics Inc (NASDAQ: KPTI) was released for 2024-09-30. The company reported revenue of $38.78 million for the quarter, compared to $36.01 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.7 percent.
